research use only

Divalproex Sodium HDAC inhibitor

Name: Divalproex Sodium
Brand: Selleck Chemicals
SKU: S1703
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S1703

Divalproex Sodium, consisting of a compound of sodium valproate and valproic acid in a 1:1 molar relationship in an enteric coated form, is a HDAC inhibitor, used in the treatment for epilepsy.

Chemical Structure

Molecular Weight: 310.41

Jump to

Quality Control

Batch: S170301 DMSO]62 mg/mL]false]Water]62 mg/mL]false]Ethanol]62 mg/mL]false Purity: 99.91%

Cited in Nature Medicine for its top-tier quality
COA
NMR
HPLC
SDS
Datasheet

99.91

Related Targets	JAK BET Histone Methyltransferase PKC PARP HIF PRMT EZH2 AMPK Histone Acetyltransferase
Other HDAC Inhibitors	ITF-2357 (Givinostat) Hydrochloride Monohydrate Fimepinostat (CUDC-907) Trichostatin A (TSA) Entinostat (MS-275) RGFP966 Quisinostat (JNJ-26481585) Dihydrochloride Tubastatin A HCl Tubastatin A Mocetinostat (MGCD0103) Ricolinostat (ACY-1215)

Solubility

In vitro
Batch:

DMSO : 62 mg/mL (199.73 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 62 mg/mL

Ethanol : 62 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	310.41	Formula	C₈H₁₆O₂.C₈H₁₅O₂.Na	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	76584-70-8	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+]

Mechanism of Action

Targets/IC₅₀/Ki	HDAC
In vitro	Divalproex sodium enhances IM-induced cell growth inhibition, apoptosis and cell cycle arrest in K562-S and K562-G cells. Divalproex sodium enhances the inhibitory effects of IM on SIRT1 expression in K562-S and K562-G cells. Divalproex sodium enhances the effect of IM on apoptosis in K562-G cells partly through SIRT1. Divalproex (500 mg/kg) significantly increases dopamine (DA) and acetylcholine (ACh) efflux in the rat hippocampus, and DA, but not ACh, efflux in the rat medial prefrontal cortex (mPFC), whereas a lower dose of Divalproex, 50 mg/kg, has no effect on DA or ACh in either region. Divalproex (50 mg/kg) combined with the atypical APDs Olanzapine (1.0 mg/kg) or Aripiprazole (0.3 mg/kg) significantly potentiates the effect of both antipsychotic drugs (APDs) on DA, but not ACh efflux in the HIP and mPFC.
References	[1] https://pubmed.ncbi.nlm.nih.gov/25449787/ [2] https://pubmed.ncbi.nlm.nih.gov/16824491/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01094249	Completed	Schizophrenia\|Bipolar Disorder\|Psychotic Disorders	Johnson & Johnson Pharmaceutical Research & Development L.L.C.	February 2009	Phase 1
NCT01060228	Completed	Schizophrenia\|Epilepsy	Johnson & Johnson Pharmaceutical Research & Development L.L.C.	January 2009	Phase 1
NCT01055938	Completed	Healthy	Dr. Reddy''s Laboratories Limited	December 2006	Phase 1
NCT01056627	Completed	Healthy	Dr. Reddy''s Laboratories Limited	December 2006	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):